By the Numbers
Medicinal Chemistry News
The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established in response to the public health emergency.
Thanks to a research collaboration between the Institute for Therapeutics Discovery & Development and Mayo Clinic, a drug that shows promise for glaucoma patients has moved to Phase I/II clinical trials.
Carston “Rick” Wagner, PhD, has been named the 2021 recipient of the American Association of Colleges of Pharmacy’s (AACP) Volwiler Research Achievement Award.